On September 8, 2026 TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, reported that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 28th Annual Global Investment Conference

Date:

Monday, September 14th

Time:

4:00pm ET

Format:

Fireside Chat & 1×1 Meetings

To register and view the presentation, please CLICK HERE.

An archived webcast of the Fireside Chat will be available on the Events Page in the investor section of TuHURA’s website.

(Press release, TuHURA Biosciences, SEP 8, 2026, https://ir.tuhurabio.com/news-events/press-releases/detail/49/tuhura-biosciences-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference [SID1234670637])